IJCS | Volume 33, Nº4, July and August 2020

435 Sources of Funding There were no external funding sources for this study. Study Association This study is not associated with any thesis or dissertation work. 1. World Health Organization. (WHO) Coronavirus disease (COVID-19) pandemica. [Cited in 2020 Apr 10]. Available from: https://www.who.int/ 2. Johns Hopkins University Medicine. Coronavirus Resource Center. COVID-19 Case Tracker. [Cited in 2020 May 05]. Available from: https:// coronavirus.jhu.edu/ 3. Fundação Oswaldo Cruz. (FIOCRUZ). Novo Coronavirus-19. [Cited in 2020 March 10]. Available from: https://portal.fiocruz.br/ 4. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 inWuhan, China: a retrospective cohort study. Lancet 2020; 395(10229):1054-62. 5. Ruan Q, Yang K, WangW, Jiang L, Song J. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med.2020 May;46(5):846-8. 6. Strabelli TMV, Uip DE.COVID-19 and the heart. Arq Bras Cardiol. 2020 Arq Bras Cardiol. 2020;114(4):598-600. 7. Zeng J, Huang J, Pan L. How to balance acute myocardial infarction and COVID-19: the protocols from Sichuan Provincial People’s Hospital. Intensive Care Med. 2020;46:1111-3. 8. Tarantini G, Fraccaro C, ChieffoA, Marchese A, Tarantino FF, Rigattieri, S, et al. Italian Society of Interventional Cardiology (GISE) position paper for Cath lab-specific preparedness recommendations for healthcare providers in case of suspected, probable or confirmed cases of COVID-19. Catheter Cardiovasc Interv. 2020 Mar 29; 10.1002/ccd.2888 References Ethics approval and consent to participate This study was approved by the Ethics Committee of the Instituto D´Or de Pesquisa e Ensino under the protocol number CAAE: 31478820.0.0000.5249. All the procedures in this study were in accordance with the 1975 Helsinki Declaration, updated in 2013. Informed consent was obtained from all participants included in the study. 9. Welt FGP, Shah PB, AronowHD, BortnickAE, Henry TD, SherwoodMW, et al. Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic: FromACC's Interventional Council and SCAI. J Am Coll Cardiol. 2020;75(18):2372-5. 10. Rodríguez-Leor O, Cid-Álvarez B, Ojeda S, Martín-Moreiras J, Rumoroso JR, López-Palop R, et al. Impacto de la pandemia de COVID-19 sobre la actividad asistencial en cardiología intervencionista en España. REC Interv Cardiol.2020;2:82-9. 11. Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. 12. Mehta SR, Wood DA, Storey RF, Mehran R, Nguyen H, Meeks B, et al. Complete Revascularization with Multivessel PCI for Myocardial Infarction. N Engl J Med. 2019 Oct 10;381(15):1411-21. 13. The European Society for Cardiology ESC Guidance for the Diagnosis andManagement of CVDisease during the COVID-19 Pandemic. [Cited in 2020 May 20]. Available from: www.escardio.org/education/covid-19 14. Nguyen JL, YangW, Ito K, Matte TD, Shaman J, Kinney PL, et al. Seasonal influenza infections and cardiovascular diseasemortality. JAMACardiol. 2016;1(3):274-81. 15. Kwong JC, Schwartz KL, Campitelli MA, Chung H, Crowcroft NS, Karnauchow T, et al. Acute Myocardial Infarction after Laboratory- Confirmed Influenza Infection. N Engl J Med. 2018;378(4):345-53. 16. Meyer P, Degrauwe S, Delden CV, Ghadri JR, Templin C. Typical takotsubo syndrome triggered by SARS-CoV-2 infection. Eur Heart J. 2020. 2020;41(19):1860. Esteves et al. Covid-19 and STEMI Int J Cardiovasc Sci. 2020; 33(4):429-435 Case Report